Patents
Isolation and transplantation of retinal stem cells
Patent Number: 7,514,259This patent uses claim language associated with method of use, but is actually teaching what appears to be a new type of retinal stem cell. The first independent claim reads:"A method of repopulating photoreceptor cells of a mammal, said method comprising the steps of: providing neuroretina-derived retinal stem cells obtained from a neurosphere from a mammalian donor; and introducing...
Inventor: Isolation and transplantation of retinal stem cells
Assignee: Young Michael J. (Gloucester, MA); Klassen Henry J. (Pasadena, CA); Shatos Marie A. (Athol, MA); Mizumoto Keiko (Higashi, JP)
Date of First Priority Issue: Friday February 11th, 2000
Cardiac muscle regeneration using mesenchymal stem cells
Patent Number: 7,514,074Mesenchymal stem cells (MSC) are universal donor cells capable of stimulating angiogenesis and clinically improving cardiac parameters in post infact patients.The current patent covers the use of mesenchymal stem cells in the improvement of heart functions. The one independent claim covers:"A method of improving ventricular wall...
Inventors: Pittenger; Mark F. (Severna Park, MD), Gordon; Stephen L. (Columbia, MD), Mackay; Alastair Morgan (Timonium, MD), Martin; Bradley J. (Ellicot City, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Monday July 14th, 1997
Definitive endoderm
Patent Number: 7,510,876Continuing Novocell's domination of IP in the area of developing commercial ES-derived products, this recent patent covers composition of matter on in vitro endoderm (eg progenitor cell of the liver, pancreas, digestive tube) derived from "multipotent" cells. The broadest claim, "An in vitro cell culture comprising human cells wherein at least 15% of said human cells are...
Inventors: D'Amour; Kevin Allen (San Diego, CA), Agulnick; Alan D. (San Marcos, CA), Baetge; Emmanuel E. (Encinitas, CA)
Assignee: Cythera, Inc. (San Diego, CA)
Date of First Priority Issue: Tuesday December 23rd, 2003
Method of treating coronary artery disease by administering FGF-4
Patent Number: 7,511,019Stimulation of angiogenesis for treatment of ischemic conditions would provide therapeutic solutions for conditions such as heart failure, peripheral artery disease, and even stroke, in which post-injury angiogenesis plays a major role. Some companies, such as Medistem, are using cells such as the Endometrial Regenerative Cells (ERC) to stimulate...
Inventors: Whitehouse; Martha J. (San Francisco, CA), Kavanaugh; W. Michael (Marin, CA)
Assignee: Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA)
Date of First Priority Issue: Tuesday October 13th, 1998
Hematopoietic stem cell identification and isolation
Patent Number: 7,510,877The hematopoietic stem cell is the most well studied stem cell, being responsible for saving hundreds of thousands of lives through allowing the procedure of bone marrow transplant to become a reality. As far back as 1984, filings on hematopoietic stem cells can be found (#4,714,680).The current patent has a new way of purifying hematopoietic stem cells...
Inventors: Yilmaz; Omer H. (Ann Arbor, MI), Kiel; Mark J. (Ann Arbor, MI), Morrison; Sean (Ann Arbor, MI), Iwashita; Toshihide (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Friday September 26th, 2003
STAT3 activated stem cell
Patent Number: 7,510,870One of the major problems in stem cell research is how to maintain the stem cell in an undifferentiated state while allowing for it to continue proliferating. In the area of embryonic stem cells this was solved by the discovery that leukemia inhibitory factor (LIF) would maintain mouse embryonic stem cells in an undifferentiated state. For human...
Inventors: Oh; Il-Hoan (Seoul, KR)
Assignee: Industry-Academic Cooperation Foundation, (Seoul, KR); The Catholic University of Korea (Seoul, KR)
Date of First Priority Issue: Friday February 15th, 2002
Treatment of cancers
Patent Number: 7,507,766Chemotherapy has cancer has numerous side effects. Most of the patents relating to protection of side effects of chemotherapy relate to protecting the hematopoietic stem cells. Other patents cover means of protecting hair follicle stem cells. The current patent covers means of protecting muscles from the effects of...
Inventors: Lazaro; Luis Lopez (Madrid, ES), Fernandez-Sousa; Jose Maria (Madrid, ES), Armand; Jean-Pierre (Villejuif-Cedex, FR), Raymond; Eric (Villejuif-Cedex, FR)
Assignee: Pharma Mar, S.A. (Madrid, ES)
Date of First Priority Issue: Thursday October 12th, 2000
1 Comment
1 Comment
Protection of cardiac myocardium
Patent Number: 7,504,379This patent has two sets of independent claims. The first covers "method of increasing survival of blood vessels" and the second "method of reducing myocardial necrosis". Both of these aims are achieved by "administering to the patient a therapeutically effective amount of platelet derived growth factor, angiopoietin-2, and vascular endothelial growth...
Inventors: Edelberg; Jay (New York, NY), Xaymardan; Munira (Toronto, CA)
Assignee: Cornell Research Foundation, Inc. (Ithaca, NY)
Date of First Priority Issue: Thursday November 14th, 2002
Embryonic stem cells and neural progenitor cells derived therefrom
Patent Number: 7,504,257This patent covers methods of generating neural progenitor cells from embryonic stem cells in vitro. In its one issued claim the inventors teach the administration of EGF and FGF-2 to serum-free media containing undifferentiated pluripotent human embryonic stem cells in order to give rise to tripotent neural progenitor cells. The neural progenitor cells are capable of...
Inventors: Reubinoff; Benjamin Eithan (Mevaseret-Zion, IL), Pera; Martin Frederick (Prahran, AU), Ben-Hur; Tamir (Ramat Sharet, IL)
Assignee: ES Cell International PTE Ltd. (Singapore, SG)
Date of First Priority Issue: Tuesday March 14th, 2000
Systems and methods for treating patients with processed lipoaspirate cells
Patent Number: 7,501,115Adipose derived stem cells have been very useful therapeutically for a variety of indications, at least from animal studies. For example, syngeneic adipose mesenchymal stem cells have been demonstrated to improve cardiac parameters in a porcine model of heart failure. Adipose derived cells have stimulated angiogenesis in models of
Assignee: Cytori Therapeutics, Inc. (San Diego, CA)
Date of First Priority Issue: Friday December 7th, 2001